The Max Foundation is proud to announce that our Chief Executive Officer Pat Garcia-Gonzalez has been named a finalist for the Union for International Cancer Control (UICC)’s CEO Award!
Pat is one of three finalists for this year’s award, alongside two friends and compatriots in the fight against cancer: Asem Mansour of King Hussein Cancer Center in Jordan, and Wondu Bekele Woldemariam of Mathiwos Wondu-YeEthiopia Cancer Society. Our thanks and congratulations go out to all three finalists for their tremendous impact and visionary leadership. The world is a better place for their contributions.
We would also like to thank the 18 different Patient Associations from around the world that sent letters in support of Pat’s nomination. You are the inspiration for all we do and we are so very grateful for your support.
The winner of the award will be announced on October 2nd at this year’s World Cancer Congress in Kuala Lumpur. Representatives from The Max Foundation and patient advocates from across Asia will be in attendance to share their knowledge, their experiences, and, of course, to cheer on Pat!
Visit the UICC website to learn more about the awards and the finalists.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Today, Spot On CML is active in 19 countries and, on June 29th, 17 patients were chosen by the treating physicians at Philippine General Hospital to take part in the program. While CML testing is available in the Philippines, it’s prohibitively expensive – placing critical diagnostic information out of reach for many patients.
A new study led by Boston University School of Public Health, The Max Foundation, and Novartis Oncology found that chronic myeloid leukemia (CML) patients taking first-line treatment in low- and middle-income countries (LMICs) as part of the Glivec International Patient Assistance Program (GIPAP) have survival rates that compare favorably to those of CML patients receiving treatment in high-income countries.
The Max Foundation has renewed and expanded its treatment-access agreement with Incyte in Europe. The agreement will now provide treatment access for up to 50 patients in Eastern Europe and Central Asia.
